Tessera Names Romanelli CEO in Pre-Data Succession

Company Tessera Therapeutics (Flagship Pioneering) Event Type Executive Leadership Transition (CEO Succession) Modality All-RNA Gene Writing Platform (Target-Primed Reverse Transcription, In Vivo Delivery) Platform Gene Writing — In Vivo Genome Editing and Lipid-Nanoparticle Delivery Indication Cross-Therapeutic (Lead Program: Alpha-1 Antitrypsin Deficiency via TSRA-196; Pipeline: Sickle…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Weekly Market Insight

Terremoto – $108M Series C Degrader Platform
Nurix–Roche BTK Degrader Deal Closes
Lilly + Ascidian – $1.9B RNA Exon Editing Deal
MeiraGTx – $400M Oberland Strategic Financing for Late-Stage Gene Therapy Programs